Onkourologiya最新文献

{"title":"International experience of using olaparib for metastatic castration-resistant prostate cancer: literature review","authors":"V. Matveev, O. Khalmurzaev, O. Evsyukova","doi":"10.17650/1726-9776-2020-16-4-197-206","DOIUrl":"https://doi.org/10.17650/1726-9776-2020-16-4-197-206","url":null,"abstract":"The following review presents a problem of metastatic castration-resistant prostate cancer and its association with germline or somatic mutations in homologous recombination repair (HRR). In 2020, olaparib was approved in the Russian Federation as a monotherapy for metastatic castration-resistant prostate cancer with germline or somatic mutations of genes involved in DNA repair by homologous recombination, after progression on therapy with new hormonal drugs. We describe a review of the main olaparib clinical trials assessing its efficacy, safety and tolerance in metastatic castration-resistant prostate cancer patients.","PeriodicalId":42924,"journal":{"name":"Onkourologiya","volume":"1 1","pages":""},"PeriodicalIF":0.1,"publicationDate":"2021-02-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"67763292","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Review of the article “Computed tomography-guided pararectal prostate fusion biopsy”","authors":"A. Zyryanov","doi":"10.17650/1726-9776-2020-16-4-98","DOIUrl":"https://doi.org/10.17650/1726-9776-2020-16-4-98","url":null,"abstract":"<jats:p>.</jats:p>","PeriodicalId":42924,"journal":{"name":"Onkourologiya","volume":"1 1","pages":""},"PeriodicalIF":0.1,"publicationDate":"2021-02-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"67764415","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical implication of kidney injury molecule (KIM-1) in blood plasma of renal-cell cancer patients","authors":"E. Gershtein, D. Naberezhnov, A. Alferov, S. Bezhanova, N. Frolova, V. Matveev, N. E. Kuslinskii","doi":"10.17650/1726-9776-2020-16-4-39-47","DOIUrl":"https://doi.org/10.17650/1726-9776-2020-16-4-39-47","url":null,"abstract":"Background. The most important task in the field of renal-cell cancer (RCC) treatment results improvement is the search and validation of the markers for its early diagnostics still absent in the clinical practice. It was established that even before the onset and/or detection of RCC the level of kidney injury molecule-1 (KIM-1) in blood plasma did increase.Objective of the study — comparative evaluation of KIM-1 levels in blood plasma of practically healthy persons, RCC cancer, benign kidney tumor patients, patients with non-oncological renal pathologies, and analysis of its role in RCC diagnostics and prognosis.Materials and methods. 125 RCC (age 33—81 years), 14 — benign kidney neoplasms (29—84 years) patients, 90patients with chronic nephritis (28—82 years) and 68 practically healthy persons (18—71 years) were included in the study. Plasma KIM-1 content was measured using Human Serum TIM-1/KIM-1/HAVCR Quantikine® ELISA kit (R&D Systems Biotechne®, USA).Results. KIM-1 level in blood plasma of RCC and chronic nephritis patients was significantly higher than in control (medians 305, 282 and 37.8pg/ml respectively, p <0.0001). The rate of KIM-1 elevation over cut-offvalue 90pg/ml corresponding to the upper 95 % confidence interval of control in RCC patients comprised 79.2 %, in patients with nephritis — 83 %, in those with benign renal tumors — 50 %. Specificity in relation to healthy control was 96 %. KIM-1 level highly significantly increased with RCC progression, and already at stage I was 4.3-fold higher by median than in control (p <0.0001). Sensitivity of stage I—IIRCC detection at cut-off 90pg/ml comprised 75 %; stage III—IV — 94 %. The highest plasma KIM-1 levels were detected in papillary cancer patients (median 644pg/ml), that was more than 2-fold higher than in clear-cell and 32-fold higher than in chromophobic RCC. Plasma KIM-1 median level was 7-fold higher in patients with G3 4RCC than in those with G12 (p <0.0001). At the cut-off KIM-1 value of 163pg/ml, corresponding to the median at stage I, significant differences in 3.5-years overall survival both in the total group: 49 % at high, 95 % at low marker level (p <0.01), and at stage I RCC: 62 % and 100 % respectively (p <0.05) — were revealed.Conclusion. Plasma KIM-1 may become the first highly sensitive marker for the early detection of RCC, but it does not allow differentiating between oncologic and non-oncologic renal pathologies. Increased basal plasma KIM-1 is an unfavorable prognostic factor irrespective of the stage of tumor progression.","PeriodicalId":42924,"journal":{"name":"Onkourologiya","volume":"1 1","pages":""},"PeriodicalIF":0.1,"publicationDate":"2021-02-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"67764443","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy and safety of radium-223 in routine clinical practice","authors":"V. Matveev, A. Markova","doi":"10.17650/1726-9776-2020-16-4-129-135","DOIUrl":"https://doi.org/10.17650/1726-9776-2020-16-4-129-135","url":null,"abstract":"Several treatment options are currently available for patients with metastatic castration-resistant prostate cancer in routine clinical practice. However, clear standards of sequential use of registered drugs have not yet been developed. Affecting bone metastases, radium-223 is one of therapeutic options for patients with castration-resistant prostate cancer and bone metastases, which was included in foreign and Russian guidelines for prostate cancer management. This article analyzes the results of treatment with radium-223 in patients with metastatic castration-resistant prostate cancer in foreign non-interventional clinical trials conducted in routine clinical practice. These trials confirmed high efficacy and safety of radium-223 demonstrated earlier in the ALSYMPCA trial. Some protocols ensured better overall survival rates and lower incidence of symptomatic skeletal events and adverse events than those in the registration study.","PeriodicalId":42924,"journal":{"name":"Onkourologiya","volume":"1 1","pages":""},"PeriodicalIF":0.1,"publicationDate":"2021-02-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"67762232","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Metastatic testicular and epididymal lesions in a patient with advanced prostate cancer: a case report and literature review","authors":"S. Reva, A. A. Lyublinskaya, D. Prokhorov, K. G. Pygamov, A. G. Tyurin, А. M. Sycheva, S. Petrov","doi":"10.17650/1726-9776-2020-16-4-207-212","DOIUrl":"https://doi.org/10.17650/1726-9776-2020-16-4-207-212","url":null,"abstract":"Prostate cancer (PCa) is a second of the most commonly diagnosed carcinoma in the male population. Usually sites of secondary lesions are lymph nodes and bones. Most cases of testicular metastases are incidentally diagnosed after orchiectomy. We present a case of 62-year-old man with metastatic castration-resistant PCa and symptomatic testicular metastasis with contralateral epididymal metastasis. Right site radical orchiectomy and left site orchiectomy was performed. The pathology report identified PCa metastases in the right testis and in the left epididymis. Testicular and epididymal metastases are uncommon in PCa. Therefore, a testicular physical examination is necessary for patients with PCa. Physicians have to keep in mind the possibility of testicular metastasis in cases of biochemical recurrence and progression of the disease.","PeriodicalId":42924,"journal":{"name":"Onkourologiya","volume":"48 1","pages":""},"PeriodicalIF":0.1,"publicationDate":"2021-02-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"67763345","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Resection of a kidney tumor with superselective targeted balloon-occluded chemoembolization","authors":"A. V. Maksimov, A. Martov, P. Neustroev, V. Alekseev, D. V. Peretolchin, L. A. Klarov, E. I. Neustroev, N. P. Kladkin","doi":"10.17650/1726-9776-2020-16-4-49-58","DOIUrl":"https://doi.org/10.17650/1726-9776-2020-16-4-49-58","url":null,"abstract":"Objective : to develop a method of laparoscopic resection of a kidney tumor with super selective balloon occlusion of the segmental renal artery and targeted chemoembolization. Another purpose is to estimate the degree of fixation of the chemotherapy drug in the kidney parenchyma. Materials and methods . The study included the results of experiments on 14 laboratory rabbits, who underwent an intra-arterial injection of the coloring substance of Ponceau S and there were determined its concentration in the renal parenchyma after fixation with a hemostatic suture for 8 days after the injection of the marker. Besides, there were included the results of 13 studies of the contrast substance of ultraravist and gadovist concentration in the renal tissue of patients after resection of the neoplasm with intra-arterial injection of the contrast substance into the parenchyma of the operated kidney. Results. The implemented study showed the presence of a high concentration of a substance injected into the renal artery and a hemostatic suture fixed to the wound edges in the kidney tissue for 6-8 days of the postoperative period. Conclusion . Laparoscopic resection of a malignant kidney tumor with a super-selective balloon occlusion of the segmental renal artery, supplemented by the injection of a targeted chemotherapy agent into the renal artery is a highly effective, safe and simple method of surgical treatment of kidney cancer with enhanced anti-relapse protection due to high concentrations of chemotherapy in the resection area.","PeriodicalId":42924,"journal":{"name":"Onkourologiya","volume":"1 1","pages":""},"PeriodicalIF":0.1,"publicationDate":"2021-02-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"67764172","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Bladder cancer: what’s new in 2019—2020","authors":"O. Karyakin","doi":"10.17650/1726-9776-2020-16-4-147-154","DOIUrl":"https://doi.org/10.17650/1726-9776-2020-16-4-147-154","url":null,"abstract":"This review aims to summarize the latest data on the treatment of bladder cancer published during the specified period Most of them are evidence-based and were obtained in randomized trials A new classification based on molecular data was proposed at a consensus meeting of pathologists A significant correlation has been demonstrated between life expectancy and morphological structure of the tumor This article covers chemotherapy regimens for patient with BCG (Bacillus Calmette-Guérin) intolerance Immunotherapeutic agents for muscleinvasive bladder cancer are being actively studied now;scientists are searching for the best treatment regimens with these drugs and their combinations with other antitumor agents The European Association of Urology has developed a new classification of intraoperative adverse events and recommendations for pharmacotherapy and surgical treatment of patients with bladder cancer during the COVID-19 pandemic In conclusion, the opinions of experts from the consensus meeting on the treatment of various forms of bladder cancer are given © 2020 ABC-press Publishing House All rights reserved","PeriodicalId":42924,"journal":{"name":"Onkourologiya","volume":"1 1","pages":""},"PeriodicalIF":0.1,"publicationDate":"2021-02-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"67762409","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"An example of late postoperative complications in a patient with urogenital rhabdomyosarcoma after cystprostatectomy","authors":"S. A. Sardalova, M. Rubanskaya, A. S. Temniy, O. A. Kapkova, O. A. Ignatenko, А. P. Kazantsev, S. Mikhailova, D. V. Rybakova, Kh. I. Jumaniyozov, P. A. Kerimov, M. А. Rubanskiy, A. Ryabov, K. Figurin","doi":"10.17650/1726-9776-2020-16-4-155-159","DOIUrl":"https://doi.org/10.17650/1726-9776-2020-16-4-155-159","url":null,"abstract":"About 20—25 % of all rhabdomyosarcomas in children are located in the urogenital zone. Due to introduction of new drug treatment protocols and the use of radiation therapy, most patients are cured by conservative methods. Only about 20 % of patients undergo surgical treatment, significant number of which are underwent organ-preserving operations. In those cases when the tumor has resistance to conservative treatment, when there is a residual tumor or relapse of the disease develops, radical organ-resecting operations are considered. Among the methods of urine derivation after cystectomy, preference is given to options that allow patients to carry out urine excretion voluntary: the formation of heterotopic reservoirs connected to the urethra or opening on the skin surfaces, which are constructed from different parts of the intestine. A clinical example of late postoperative complication is presented — a calculi formation within the pouch 7 years after radical cystprostatectomy with continent urinary diversion in a patient operated for urogenital rhabdomyosarcoma.","PeriodicalId":42924,"journal":{"name":"Onkourologiya","volume":"1 1","pages":""},"PeriodicalIF":0.1,"publicationDate":"2021-02-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"67762471","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Dynamics of survival of patients with prostate cancer at the population level, taking into account the stage of the disease and place of residence","authors":"R. Andreeva, R. S. Nizamova, A. Andreev","doi":"10.17650/1726-9776-2020-16-4-120-128","DOIUrl":"https://doi.org/10.17650/1726-9776-2020-16-4-120-128","url":null,"abstract":"Background. Prostate cancer (PCa) is rapidly gaining a leading position in the incidence of malignant tumors among men. With a general decrease in mortality from all oncological diseases, mortality from PCa in the Russian Federation is increasing: in 2005 there were 8192 deaths, in 2015 - 11987.Objective of the study. Calculation and assessment of survival rates for patients with PCa in the Samara region for the period from 2010 to 2016, taking into account the stage of the disease, the place of residence of patients, a comparative analysis of the observed, adjusted and relative 5-year survival for this disease in a number of regions of Russia and in the world.Materials and methods. The object of the study was all registered patients for the period 2010-2016, with the first established PCa.The calculation and analysis of the observed (OS), adjusted (AS) and relative (OS) survival of 7670 patients with PCa taking into account the stage of the disease and place of residence (urban residents — 6408people, rural — 1262), registered in the database of the population cancer registry of Samara Region Clinical Oncology Clinic. The start date of the study is January 1, 2010, the end date is December 31, 2019. The calculation of survival was carried out by the dynamic (actuarial) method.Results. When assessing the survival of patients with PCa, lower rates of observed survival were observed than adjusted, which indicates the presence of intercurrent causes of death.During the study period, an inverse dependence of survival on the prevalence of the tumor process was revealed. The level of observed survival and adjusted survival of all patients is associated in the survival range at stages II—III: 1-year-old observed survival — 89.1 % (adjusted survival — 92.3 %), 5-year-old observed survival — 62.6 % (adjusted survival — 76.6 %).The adjusted and relative survival rate for the urban population is higher than for the rural population, which may indicate an insufficient level of access to cancer care for patients with PCa in rural areas: the indicators of 1-year adjusted survival of urban residents are higher — 3.3 % (relative survival — 2.4 %), 5-year-old adjusted survival—7.4 % (relative survival — 10.3 %) than in patients registered in rural hospitals.Conclusion. A comparative analysis of indicators of 1- and 5-year survival of patients with PCa in the Samara region and a number of regions of the Russian Federation for 2006—2010 revealed that domestic indicators of 1-year and 5-year relative survival are slightly lower than the European average for 2000—2007. The range of indicators of the 5-year relative survivalfor 2010—2013 in the Samara region amounted to 82.2—93.1 %.","PeriodicalId":42924,"journal":{"name":"Onkourologiya","volume":"1 1","pages":""},"PeriodicalIF":0.1,"publicationDate":"2021-02-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"67762797","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The role of microRNA in the diagnosis of prostate cancer","authors":"D. Dolotkazin, M. Shkurnikov, B. Alekseev","doi":"10.17650/1726-9776-2020-16-4-172-180","DOIUrl":"https://doi.org/10.17650/1726-9776-2020-16-4-172-180","url":null,"abstract":"Д.Р. Долотказин1, М.Ю. Шкурников1 , Б.Я. Алексеев1, 2 1Московский научно-исследовательский онкологический институт им. П.А. Герцена – филиал ФГБУ «Национальный медицинский исследовательский центр радиологии» Минздрава России; Россия, 125284 Москва, 2-й Боткинский проезд, 3; 2кафедра онкологии Медицинского института непрерывного образования ФГБОУ ВО «Московский государственный университет пищевых производств»; Россия, 125080 Москва, Волоколамское шоссе, 11","PeriodicalId":42924,"journal":{"name":"Onkourologiya","volume":"1 1","pages":""},"PeriodicalIF":0.1,"publicationDate":"2021-02-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"67763577","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}